<DOC>
	<DOCNO>NCT01949935</DOCNO>
	<brief_summary>The hypothesis application Mupirocin nose coronary artery bypass graft surgery reduce incidence surgical site infection .</brief_summary>
	<brief_title>Efficacy Study Mupirocin Infection After Coronary Artery Bypass Grafting</brief_title>
	<detailed_description>Mupirocin apply naris effective eradicate nasal carriage Staphylococcus specie . Abundant evidence document majority gram positive surgical site infection share bacterial phenotype identical nasal phage type . Conflicting literature exist regard efficacy mupirocin reduce incidence surgical site infection . A randomized prospective double-blind placebo-controlled trial need help settle question set coronary artery bypass graft surgery surgical site infection carry significant morbidity , cost , mortality .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Surgical Wound Infection</mesh_term>
	<mesh_term>Mupirocin</mesh_term>
	<criteria>Adults &gt; 18 year old undergoing Coronary Artery Bypass Grafting Surgery ( CABG ) without concomitant cardiac valve surgery cardiac surgery , Median sternotomy wound Capable inform consent Allergy mupirocin component Pregnant lactate female Emergency surgery Preexisting ongoing infection</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Mupirocin</keyword>
	<keyword>Surgical Site Infections</keyword>
	<keyword>Coronary Artery Bypass Grafting</keyword>
</DOC>